A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06512337

Acronym

ADMIRE

Enrollment

153

Registered

2024-07-22

Start date

2025-01-20

Completion date

2027-03-11

Last updated

2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Keywords

Plaque psoriasis

Brief summary

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Interventions

DRUGDeucravacitinib

As per product label

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participant aged 18 years or older * Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10% * Participant newly initiated deucravacitinib according to the label * Provided written informed consent to participate in the study

Exclusion criteria

* Participating in or planning to participate in an interventional clinical trial * Concomitant use of other systemic treatments for psoriasis at baseline * Prior treatment of deucravacitinib

Design outcomes

Primary

Measure	Time frame
Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score	Week 16
Participant psoriasis Body Surface Area (BSA) involvement	Week 16
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3	Week 16

Secondary

Measure	Time frame
Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response	Baseline and Weeks 4, 12, 24, 36, and 52
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5	Baseline and Weeks 4, 12, 24, 36, and 52
Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline	Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in Body Surface Area (BSA) involvement from baseline to follow-up	Weeks 4, 12, 24, 36, and 52
Static Physician's Global Assessment (sPGA) 0/1 response at follow-up	Weeks 4, 12, 24, 36, and 52
Participants change in Static Physician's Global Assessment (sPGA) score from baseline	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in participant Dermatology Life Quality Index (DLQI) score from baseline	Baseline and Weeks 4, 12, 16, 24, 36, and 52

Countries

China

Contacts

STUDY_DIRECTORBristol-Myers Squibb

Bristol-Myers Squibb

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026